EC Approves Sobi’s Aspaveli for PNH

EC Approves Sobi’s Aspaveli for PNH

By, Admin 9 May 2024

European Commission approves Sobi’s Aspaveli for use among treatment naïve adult patients with PNH

Overview

Sobi announced that the European Commission (EC) has approved an indication extension for Aspaveli (pegcetacoplan) for treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have haemolytic anaemia.

Previous Approvals

  • Aspaveli is already approved in Europe for the treatment of adults with PNH who are anaemic after treatment with a C5 inhibitor for at least three months. 
  • Aspaveli is now the first C3 inhibitor approved for first-line treatment of PNH in Europe, offering effective outcomes by improving haemoglobin and other clinical markers due to its unique mode of action.

Words from CMO: Sobi

  • “Today’s approval underscores the robust clinical data supporting Aspaveli's efficacy and safety profile, offering healthcare professionals and patients an expanded toolkit for effectively managing PNH,” said Lydia Abad-Franch MD, head of R&D and medical affairs, and chief medical officer at Sobi. 
  • “European patients will now be able to initiate treatment with Aspaveli at diagnosis or switch from their current C5 inhibitor treatment if they present indicators of haemolytic anaemia. This important milestone reflects our dedication to improving treatment options for those affected by this rare and complex condition.”

About PNH

  • PNH is a rare, chronic and life-threatening blood disorder where uncontrolled complement activation leads to the destruction of oxygen-carrying red blood cells. 
  • Characterised by persistently low haemoglobin, PNH can result in frequent transfusions and debilitating symptoms such as severe fatigue caused by anaemia. 
  • Despite improvements with C5 inhibitor treatment, up to 86 per cent of people with PNH treated with C5 inhibitors remain anaemic, according to cross-sectional surveys conducted in US and EU.

APL2-308 Trial

  • The indication extension is based on data from APL2-308 (PRINCE, NCT04085601), an open-label, randomised, comparator-controlled study that enrolled patients with PNH who had not been treated with any complement inhibitor within three months prior to enrolment and with haemoglobin levels less than the lower limit of normal and lactate dehydrogenase levels =1.5 times the upper limit of normal. 
  • Efficacy and safety of Aspaveli was evaluated over a duration of 26 weeks compared to standard of care (e.g., transfusions, corticosteroids, supplements such as iron, folate, and vitamin B12; excluding complement inhibitors).

Pegcetacoplan

Aspaveli is the European trade name for pegcetacoplan, which is known as Empaveli in the United States where it is also approved for the treatment of adults with PNH and commercialised by Apellis.

About Aspaveli/Empaveli

  • Aspaveli/Empaveli (pegcetacoplan) is a targeted C3 therapy designed to regulate excessive activation of the complement cascade, part of the body’s immune system, which can lead to the onset and progression of many serious diseases. 
  • Pegcetacoplan is approved for the treatment of paroxysmal nocturnal haemoglobinuria (PNH) as Aspaveli/Empaveli in the European Union, United States, and other countries globally. 
  • Aspaveli/Empaveli is also under investigation for other rare diseases across haematology and nephrology.

Global co-development Rights

Sobi and Apellis have global co-development rights for systemic pegcetacoplan. Sobi has exclusive ex-US commercialisation rights for systemic pegcetacoplan, and Apellis has exclusive US commercialisation rights for systemic pegcetacoplan and retains worldwide commercial rights for ophthalmological pegcetacoplan, including for geographic atrophy (GA).

About Sobi

  • Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. 
  • Providing reliable access to innovative medicines in the areas of haematology, immunology, and specialty care, Sobi has approximately 1,800 employees across Europe, North America, the Middle East, Asia, and Australia. In 2023, revenue amounted to SEK 22.1 billion.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!